Search for: [Abstract = "subset of orphan drugs used in treatment of oncology diseases showed that the highest share of drugs with any recommendation was observed in Poland, and the lowest, in Latvia and Romania. The share of reimbursed drugs was the lowest in Latvia and the highest in Poland. Analysis of public expenditures revealed that the reimbursement of oncology orphan drugs is associated with a growing burden for the public budget, with an average 3\-year increase in expenses of 68%, as compared with an increase of only 8.5% in the total GDP and of 9.3% in GDP per capita among EU\-CEE countries. The total expenditures on the reimbursement of oncology orphan drugs varied among countries and was highly correlated with the total national GDP but not with GDP per capita. Expenditures per capita also were not significantly correlated with GDP per capita."]

Number of results: 1